JSPR (Jasper Therapeutics) Other Financing: $0.00 Mil (TTM As of Mar. 2026)


JSPR Jasper Therapeutics Inc JSPR
24 GF Score
Price $0.43
! 1 Warning Sign
View Full Analysis

What is Jasper Therapeutics Other Financing?

Jasper Therapeutics JSPR -5.19% 24 Other Financing is $0.00 Mil as of Mar. 2026. GuruFocus rates JSPR with a GF Score™ of 24/100. The stock has 1 warning sign investors should review.

Jasper Therapeutics's Other Financing for the three months ended in Mar. 2026 was $0.00 Mil.

Jasper Therapeutics's Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 was $0.00 Mil.

Jasper Therapeutics Other Financing Historical Data

* Premium members only.

The historical data trend for Jasper Therapeutics's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jasper Therapeutics Other Financing Chart

Jasper Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial 90.22 0.00 -0.51 0.69 0.24

Jasper Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
JSPR
24GF Score
Jasper Therapeutics Inc JSPR
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jasper Therapeutics Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of $0.00 Mil mean?
Jasper Therapeutics (JSPR) has a Other Financing of $0.00 Mil as of Mar. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Jasper Therapeutics and its competitors.
Is Jasper Therapeutics' Other Financing too high?
Jasper Therapeutics' current Other Financing is $0.00 Mil. Overall, Jasper Therapeutics has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Jasper Therapeutics' Other Financing compare to CVKD and BRTX?
Jasper Therapeutics' Other Financing of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Jasper Therapeutics and its competitors. Jasper Therapeutics's current Other Financing is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jasper Therapeutics stock overvalued right now?
Jasper Therapeutics (JSPR) has a current Other Financing of $0.00 Mil. The current Other Financing is $0.00 Mil. Jasper Therapeutics' overall GF Score™ is 24/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Jasper Therapeutics (JSPR), the current Other Financing is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Jasper Therapeutics Business Description

Address 2200 Bridge Parkway, Suite 102, Redwood, CA, USA, 94065
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.
24GF Score

Get the complete analysis for JSPR

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.43
Price